Nicotinamide riboside (NR) Increases NADP

In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.

Studies in mice have shown that boosting the levels of this cell metabolite—known as NAD —can produce multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. Levels of NAD diminish with age, and it has been suggested that loss of this metabolite may play a role in age-related health decline.


The human trial involved six men and six women, all healthy. Each participant received single oral doses of 100 mg, 300 mg, or 1,000 mg of NR in a different sequence with a seven-day gap between doses. After each dose, blood and urine samples were collected and analyzed by Brenner’s lab to measure various NAD metabolites in a process called metabolomics. The trial showed that the NR vitamin increased NAD metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses.

“This trial shows that oral NR safely boosts human NAD metabolism,” Brenner says. “We are excited because everything we are learning from animal systems indicates that the effectiveness of NR depends on preserving and/or boosting NAD and related compounds in the face of metabolic stresses. Because the levels of supplementation in mice that produce beneficial effects are achievable in people, it appears than health benefits of NR will be translatable to humans safely.”


Folksonomies: longevity supplements

/health and fitness/disease (0.371550)
/health and fitness/disease/cholesterol (0.331927)
/health and fitness/disease/diabetes (0.202250)

NR (0.963912 (positive:0.746953)), NAD metabolism (0.960786 (neutral:0.000000)), various NAD metabolites (0.955472 (neutral:0.000000)), human NAD metabolism (0.926066 (neutral:0.000000)), single oral doses (0.827622 (neutral:0.000000)), newly discovered form (0.826272 (neutral:0.000000)), cellular energy production (0.813398 (neutral:0.000000)), multiple health benefits (0.794592 (positive:0.385910)), NAD diminish (0.792779 (negative:-0.552808)), nicotinamide riboside (0.788911 (neutral:0.000000)), age-related health decline (0.784569 (negative:-0.653972)), NR vitamin (0.780876 (neutral:0.000000)), oral NR (0.762392 (neutral:0.000000)), cell metabolite (0.636989 (neutral:0.000000)), Vitamin B3 (0.617728 (neutral:0.000000)), increases levels (0.605169 (neutral:0.000000)), longer lifespan (0.589464 (neutral:0.000000)), clinical trial (0.583734 (neutral:0.000000)), nerve damage (0.581478 (negative:-0.538913)), DNA damage (0.575852 (neutral:0.000000)), cell metabolite—known (0.571337 (positive:0.385910)), seven-day gap (0.567987 (neutral:0.000000)), blood sugar (0.565155 (neutral:0.000000)), urine samples (0.554176 (neutral:0.000000)), metabolic stresses (0.553137 (positive:0.802206)), human trial (0.544572 (neutral:0.000000)), different sequence (0.544232 (neutral:0.000000)), animal systems (0.541230 (positive:0.802206)), beneficial effects (0.534924 (positive:0.734966)), related compounds (0.531308 (positive:0.802206))

NAD:Company (0.823465 (positive:0.802206)), Brenner:Person (0.658746 (neutral:0.000000)), Nicotinamide riboside:Person (0.632561 (neutral:0.000000)), blood sugar:FieldTerminology (0.517421 (neutral:0.000000)), DNA damage:HealthCondition (0.510335 (neutral:0.000000)), energy production:FieldTerminology (0.413845 (neutral:0.000000)), seven-day:Quantity (0.413845 (neutral:0.000000)), 1,000 mg:Quantity (0.413845 (neutral:0.000000)), 100 mg:Quantity (0.413845 (neutral:0.000000)), 300 mg:Quantity (0.413845 (neutral:0.000000))

Metabolism (0.982013): dbpedia | freebase
Nicotinamide adenine dinucleotide (0.646733): dbpedia | freebase
Metabolomics (0.483423): dbpedia | freebase | yago
Nutrition (0.482976): dbpedia | freebase | opencyc
Photosynthesis (0.441072): dbpedia | freebase
Niacin (0.438636): dbpedia | freebase
Clinical trial (0.424243): dbpedia | freebase
Human (0.370430): dbpedia | freebase | opencyc
Protein (0.364705): dbpedia | freebase | opencyc
Health care (0.346982): dbpedia | freebase | opencyc
Metabolome (0.345067): dbpedia | freebase
Effectiveness (0.341894): dbpedia | opencyc
Metabolite (0.330250): dbpedia | freebase
Health (0.322435): website | dbpedia | freebase | opencyc
Pharmacology (0.300706): dbpedia | freebase | opencyc
Gene (0.300311): dbpedia | freebase
Adenosine triphosphate (0.293851): dbpedia | freebase | opencyc
Enzyme (0.283024): dbpedia | freebase | opencyc
DNA (0.281569): website | dbpedia | freebase | yago
Epidemiology (0.281417): dbpedia | freebase | opencyc
Bacteria (0.267858): dbpedia | freebase | opencyc
Dose (0.260259): dbpedia
DNA repair (0.253750): dbpedia | freebase | yago
The Trial (0.253392): dbpedia | freebase | yago
Health insurance (0.252590): dbpedia | freebase | opencyc
Carbohydrate (0.252134): dbpedia | freebase
Blood sugar (0.248954): dbpedia | freebase
Boost Mobile (0.245654): website | dbpedia | freebase | yago | crunchbase
Human anatomy (0.245005): dbpedia | freebase
Clinical research (0.240715): dbpedia | freebase

 First human clinical trial for nicotinamide riboside
Electronic/World Wide Web>Internet Article:  Loop, (October 10, 2016), First human clinical trial for nicotinamide riboside, Retrieved on 2017-05-25
  • Source Material []
  • Folksonomies: longevity